Skip to Content

Darzalex Approval History

  • FDA approved: Yes (First approved November 16th, 2015)
  • Brand name: Darzalex
  • Generic name: daratumumab
  • Dosage form: Injection
  • Company: Janssen Biotech, Inc.
  • Treatment for: Multiple Myeloma

Darzalex (daratumumab) is a human anti-CD38 monoclonal antibody indicated for the treatment of patients with multiple myeloma.

Darzalex binds with high affinity to the transmembrane ectoenzyme CD38 on the surface of multiple myeloma cells. It works by inducing rapid tumor cell death.

Darzalex is administered via intravenous infusion. Patients are given antihistamine, antipyretic, and corticosteroid medicines before each dose, and corticosteroids after each dose to reduce the risk of infusion reactions.

Darzalex may cause serious reactions, including infusion reactions. The most common side effects reported in clinical studies were fatigue, nausea, back pain, pyrexia, cough, and upper respiratory tract infection.

Development History and FDA Approval Process for Darzalex

DateArticle
Jun 16, 2017Approval Genmab Announces U.S. FDA Approval of Darzalex (daratumumab) in Combination with Pomalidomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
Nov 21, 2016Approval Darzalex (daratumumab) Approved by FDA in Combination with Two Standard of Care Regimens for the Treatment of Patients with Multiple Myeloma Who Have Received At Least One Prior Therapy
Nov 16, 2015Approval FDA Approves Darzalex (daratumumab) for Patients with Previously Treated Multiple Myeloma
Sep  4, 2015U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma
Jun  5, 2015Janssen Initiates Rolling Submission of BLA for Daratumumab for the Treatment of Multiple Myeloma
Feb  3, 2015Genmab Announces Preliminary Results in Phase II Study of Daratumumab in Double Refractory Multiple Myeloma
May  1, 2013Daratumumab Receives Breakthrough Therapy Designation in Double Refractory Multiple Myeloma from U.S. FDA
Aug 30, 2012Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide